One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.

Publication date: Dec 01, 2024

To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long-term antibody durability in hematological patients. We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12-month follow-up period in our center in Ostrava, Czech Republic. Antibody response for the whole cohort exceeded 74% through the whole 12-month follow-up. Lowest seroconversion was observed in CLL cohort (20/41, 48. 8%), patients who received anti-CD20 therapy 

Open Access PDF

Concepts Keywords
3rd Adult
Czech Aged
Month Aged, 80 and over
Mrna Antibodies, Viral
Vaccinated Antibodies, Viral
Cancer
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
COVID‐19
Czech Republic
Female
Follow-Up Studies
Hematologic Neoplasms
Humans
Immunization, Secondary
Leukemia
Lymphoma
Male
Middle Aged
mRNA Vaccines
mRNA Vaccines
Myeloma
SARS-CoV-2
Time Factors
Vaccination

Semantics

Type Source Name
disease IDO immune response
disease MESH COVID-19
disease MESH Hematological Malignancies
disease MESH seroconversion
disease IDO blood
disease MESH neoplasms
disease MESH leukemia
pathway REACTOME Reproduction
disease MESH emergency
disease MESH neutropenia
disease MESH infection
drug DRUGBANK Ademetionine
disease IDO facility
drug DRUGBANK Potassium Chloride
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
drug DRUGBANK Creatinine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK L-Alanine
disease IDO protein
disease IDO assay
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Coenzyme M
disease MESH syndrome
disease MESH multiple myeloma
disease MESH lymphoma
disease MESH chronic lymphocytic leukemia
drug DRUGBANK L-Leucine
disease MESH acute lymphoblastic leukemia
drug DRUGBANK Venetoclax
disease MESH myelodysplastic syndrome
disease MESH monoclonal gammopathy
disease MESH non Hodgkin’s lymphoma
disease MESH chronic myeloid leukemia
pathway KEGG Chronic myeloid leukemia
disease MESH polycythemia vera
disease MESH primary myelofibrosis
disease MESH thrombocythemia
disease MESH Hodgkin’s lymphoma
disease MESH follicular lymphoma
disease MESH macroglobulinemia
disease MESH amyloidosis
disease MESH paresis
disease IDO history
drug DRUGBANK Methionine
drug DRUGBANK Trestolone
disease MESH Acute Myeloid Leukemia
pathway KEGG Acute myeloid leukemia
disease MESH Infectious Diseases
disease MESH Complications
disease MESH Immunocompromised Host
drug DRUGBANK Dimercaprol
disease MESH Hematological Diseases
drug DRUGBANK Tretamine

Original Article

(Visited 2 times, 1 visits today)